Abstract

Introduction: In this study, we aim to analyze the effect of total body irradiation (TBI) on neutrophil and thrombocyte engraftment durations in acute leukemia (AL) patients who achieved allogeneic hematopoietic stem cell transplantation (Allo-SCT) at our center.Methods: The data of 193 acute leukemia patients who were performed Allo-SCT from matched-related donors were analyzed retrospectively.Results: Thrombocyte engraftment duration was statistically shorter (12 days) in acute lymphoblastic leukemia (ALL) patients who received TBI-based conditioning when compared to ALL patients who received non-TBI-based conditioning (14 days; p=0.037). On the other hand, no statistically significant difference was observed between acute leukemia patients who received TBI or non-TBI-based conditioning regarding neutrophil engraftment duration.Conclusion: We found that TBI had a favorable impact on thrombocyte engraftment (TE) rather than neutrophil engraftment (NE) in Allo-SCT in patients with acute leukemia. TBI might have an impact on the engraftment of thrombocytes as per than neutrophils may be attributed to immune mechanisms and microenvironment in the patient’s bone marrow (BM).

Highlights

  • In this study, we aim to analyze the effect of total body irradiation (TBI) on neutrophil and thrombocyte engraftment durations in acute leukemia (AL) patients who achieved allogeneic hematopoietic stem cell transplantation (Allo-SCT) at our center

  • We found that TBI had a favorable impact on thrombocyte engraftment (TE) rather than neutrophil engraftment (NE) in Allo-SCT in patients with acute leukemia

  • No statistical difference was found between acute myeloid leukemia (AML) and Acute lymphoblastic leukemia (ALL) patients regarding median NE duration (15 days, p=0.9)

Read more

Summary

Introduction

We aim to analyze the effect of total body irradiation (TBI) on neutrophil and thrombocyte engraftment durations in acute leukemia (AL) patients who achieved allogeneic hematopoietic stem cell transplantation (Allo-SCT) at our center. The most frequently seen AL type is acute myeloid leukemia (AML) and it has an incidence of 5-8/100.000 [1,2]. Acute lymphoblastic leukemia (ALL) is the most frequently seen AL type in children In adults, it has an incidence of 1.28/100.000 and it is less commonly observed compared to AML [3]. Allogeneic hematopoietic stem cell transplantation (Allo-SCT) is used as a curative treatment in patients with relapsed, refractory, or high-risk acute leukemia [4,5,6]. Several risk factors have been identified for graft failure that may be related to the patient, the donor, or the transplant procedure [10]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call